My watch list
my.bionity.com  
Login  

CureVac enters clinical phase with mRNA vaccine

First data expected on intramuscular application of the newly developed vaccine

25-Oct-2018

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally optimized mRNA technology delivered using a lipid nanoparticle (LNP), tailored to provide the vaccine with a strong, safe and persistent immune response. The study will assess the safety, reactogenicity, and the potential protective immune response of the vaccine. 

CV7202 is a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein, RABV-G, formulated with next generation LNP. CureVac’s platform of mRNA-based therapeutics optimizes the properties of mRNA, including stability and immunogenicity, using enhanced sequences of naturally occurring building blocks. CureVac’s technology stimulates the immune system to mount a response against an antigen of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases, such as rabies, as well as immunotherapies for the treatment of cancer. 

“The first study participant enrolled in this rabies clinical trial is a significant milestone for CureVac, and allows the company to demonstrate its ability to trigger an immune response in vaccine naïve populations, which is different from vaccines just boosting an already existing immune response such as a flu vaccination,” said Dan Menichella, Chief Executive Officer of CureVac. “Our goal is to significantly improve today’s commercial three-to-five shot regimen rabies vaccines with a one or two shot solution that has a markedly longer duration. With this trial, we are taking an important step toward further validating the potential of our mRNA-based vaccine platform and therapeutic pipeline that will soon include additional oncology and rare diseases candidates.”

Facts, background information, dossiers
  • therapeutics
  • mRNA vaccines
  • vaccination
More about CureVac
  • News

    CureVac Welcomes Two Members to its Supervisory Board

    CureVac AG announced that Timothy Wright, M.D. and Craig Tooman were elected as independent directors to CureVac’s Supervisory Board at the Company’s Annual General Meeting. These new members will support CureVac’s mission to use mRNA to revolutionize human health with their vast drug devel ... more

    CEPI awards US$ 34M contract to CureVac

    The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG have announced a partnership agreement worth up to US$ 34 million for the ongoing development of The RNA Printer™ prototype—a transportable, down-scaled, automated messenger RNA (mRNA) printing facility. This platform ... more

    CureVac Announces New Management Structure

    CureVac AG announced that Founder and Chief Executive Officer, Dr. Ingmar Hoerr, intends to transition from his current CEO position to the Supervisory Board at the upcoming Annual General Meeting on June 20, 2018 and Hoerr stand for election as Chairman of the Supervisory Board afterwards. ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE